Evaxion Biotech A/S
NASDAQ:EVAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evaxion Biotech A/S
Net Income
Evaxion Biotech A/S
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Net Income
-$7.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Net Income
kr1.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
27%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income
kr6.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Net Income
-$21.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income
-€228m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-21%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income
kr1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
Evaxion Biotech A/S
Glance View
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
See Also
What is Evaxion Biotech A/S's Net Income?
Net Income
-7.7m
USD
Based on the financial report for Dec 31, 2025, Evaxion Biotech A/S's Net Income amounts to -7.7m USD.
What is Evaxion Biotech A/S's Net Income growth rate?
Net Income CAGR 5Y
12%
Over the last year, the Net Income growth was 27%. The average annual Net Income growth rates for Evaxion Biotech A/S have been 31% over the past three years , 12% over the past five years .
